First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis.
Yinghong Wang, Christopher Fan, Krishnavathana Varatharajalu et al.
✦ AI-curated · Sources linked
In 30 seconds
This preliminary clinical trial evaluated first-line fecal microbiota transplantation (FMT) for immune checkpoint inhibitor-mediated diarrhea and colitis (IMDC), using multi-omics profiling. Clinical response occurred in 10 (76.9%) patients, with a median time to clinical improvement of 1.5 (1-10.5) days. Among responders with samples collected before and after FMT, 6 (75%) had increased alpha-diversity. Immune-cell abundance scores that were elevated before FMT decreased afterward. The findings suggest potential biological changes associated with response, but the abstract describes a small cohort and does not establish comparative efficacy.
Key findings
- Clinical response was reported in 10 (76.9%) patients; median time to clinical improvement was 1.5 (1-10.5) days.
- Among responders with baseline and follow-up samples, 6 (75%) showed increased alpha-diversity after FMT.
- Abundance scores for several immune-cell populations elevated before FMT decreased after treatment.
Why it matters
IMDC can complicate ICI therapy, and this preliminary study reports clinical improvement after FMT used as first-line management, alongside changes in microbial diversity and immune-cell profiles. These observations may help inform further investigation of FMT in this setting, while the small cohort and absence of a stated comparator limit conclusions about efficacy.
What to keep in mind
The abstract describes a small cohort and preliminary analysis; it does not report a comparator group.